Discover clinical outcomes with iGlarLixi versus Premix BIAsp 30 in the SoliMix Randomized Controlled Trial leading to advancing therapy in sub-optimally controlled basal insulin-treated Type-2 diabetes.

MAT-BH-2300623/v1/November2023

SoliMix Study Results Summary

EMPOWER Study in Saudi Arabia

Treatment simplification of complex insulin regimens in T2D

Advancing Therapy with iGlarLixi: Differentiation from other complex regimens

You Will Now Be Leaving the Site